Date: 2011-02-17
Type of information: Fundraising
Company: Orphazyme (Denmark)
Investors: Sunstone Capital (Denmark) - Novo A/S (Denmark)
Amount: €3 million
Funding type: extension of a seed financing round
Planned used:
Others: Orphazyme has extended its seed financing by raising €3 million (22 mDDK) from new investor Sunstone Capital as well as existing shareholder Novo A/S. In conjunction with the investment, Bo Jesper Hansen, Chairman of the board at public company Swedish Orphan Biovitrum, and Sten Verland, Partner Sunstone Capital, will join the board of directors. They add significant expertise and experience with the development and commercialization of orphan drugs.
Therapeutic area: Rare diseases
